Meeting
2013 Genitourinary Cancers Symposium
Association of a 2-weeks-on and 1-week-off schedule of sunitinib with decreased toxicity in metastatic renal cell carcinoma.
Authors
Yana George Najjar
Cleveland Clinic Foundation, Cleveland, OH
Yana George Najjar , Paul Elson , Laura S. Wood , Jorge A. Garcia , Robert Dreicer , Brian I. Rini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 406)
DOI
10.1200/jco.2013.31.6_suppl.406
Abstract #
406
Poster Bd #
E11
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
A phase II study of alternative sunitinib scheduling in patients with metastatic renal cell carcinoma.
First Author: Eric Jonasch
Poster
2022 ASCO Genitourinary Cancers Symposium
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analysis of SURF study.
First Author: Antoine Thiery-Vuillemin
Poster
2018 Genitourinary Cancers Symposium
Treatment modification with sunitinib in first-line (1L) metastatic renal cell carcinoma (mRCC): An analysis of the STAR-TOR registry.
First Author: Martin Boegemann
Poster
2017 ASCO Annual Meeting
Phase II study of alternate sunitinib schedule in patients with metastatic renal cell carinoma.
First Author: Eric Jonasch